945 related articles for article (PubMed ID: 29890986)
21. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
22. A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma.
Li JP; Chen SL; Liu XM; He X; Xing S; Liu YJ; Lin YH; Liu WL
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27854304
[TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities.
Chen Z; Zhao G; Chen F; Xia J; Jiang L
BMC Cancer; 2019 Apr; 19(1):329. PubMed ID: 30961549
[TBL] [Abstract][Full Text] [Related]
24. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
[TBL] [Abstract][Full Text] [Related]
25. Biological characteristics of pediatric renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
Song HC; Sun N; Zhang WP; He L; Fu L; Huang C
J Pediatr Surg; 2014 Apr; 49(4):539-42. PubMed ID: 24726108
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
Zhang Y; Jiang C; Li J; Sun J; Qu X
Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
[TBL] [Abstract][Full Text] [Related]
27. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
28. MDCT findings of renal cell carcinoma associated with Xp11.2 translocation and TFE3 gene fusion and papillary renal cell carcinoma.
Woo S; Kim SY; Lee MS; Moon KC; Kim SH; Cho JY; Kim SH
AJR Am J Roentgenol; 2015 Mar; 204(3):542-9. PubMed ID: 25714283
[TBL] [Abstract][Full Text] [Related]
29. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
He J; Chen X; Gan W; Zhu B; Fan X; Guo H; Jia R
Future Oncol; 2015; 11(24):3243-52. PubMed ID: 26169997
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic strategies and predictive models for Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma in adults based on data of two Chinese medical centers.
Yang Y; Zhao C; Wang Z; Liu F; Zhao M; Yang H; Chen J; Chen X; Shi M; Jiang D; Luo X; Duan Y; Bai Y
Aging (Albany NY); 2024 Jan; 16(2):1696-1711. PubMed ID: 38261736
[TBL] [Abstract][Full Text] [Related]
31. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
32. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
33. Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis.
Qiu Rao ; Bing Guan ; Zhou XJ
Int J Surg Pathol; 2010 Dec; 18(6):458-64. PubMed ID: 20643670
[TBL] [Abstract][Full Text] [Related]
34. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.
Komai Y; Fujiwara M; Fujii Y; Mukai H; Yonese J; Kawakami S; Yamamoto S; Migita T; Ishikawa Y; Kurata M; Nakamura T; Fukui I
Clin Cancer Res; 2009 Feb; 15(4):1170-6. PubMed ID: 19228722
[TBL] [Abstract][Full Text] [Related]
35. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features of Xp11.2 translocation renal cell carcinoma.
Lim B; You D; Jeong IG; Kwon T; Hong S; Song C; Cho YM; Hong B; Hong JH; Ahn H; Kim CS
Korean J Urol; 2015 Mar; 56(3):212-7. PubMed ID: 25763125
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas.
Zhou J; Zhao L; Yang Z; Chen Y; Wu X; Xue W
BMC Urol; 2022 Jul; 22(1):109. PubMed ID: 35850864
[TBL] [Abstract][Full Text] [Related]
39. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
